Endocrine Abstracts

Introduction: Patients with diabetes mellitus require insulin with disease progression to attain or maintain glycaemic targets. Patients and physicians work together to balance the advantages of improved glycaemic control with the risk of hypoglycaemia and increasing regimen complexity. Insulin Degludec (Tresiba) is an ultra-long-acting insulin analogue launched in the UK in March 2013 and is available in two strengths, 100 and 200 units/ml.Method: Retro...